Log In
BCIQ
Print this Print this
 

AB-16B5

  Manage Alerts
Collapse Summary General Information
Company Alethia BioTherapeutics Inc.
DescriptionIgG2 mAb against clusterin (CLU; APOJ)
Molecular Target Clusterin (CLU) (APOJ)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerInternational Biotech Center Generium (IBC Generium)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/03/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today